Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 4/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270190 | 0.80 | F10 (0.57) | F10 | |
| SCHEMBL12507531 | 0.77 | F10 (0.36) | F10 | |
| SCHEMBL12507710 | 0.76 | STS (0.41) | STSALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL12507971 | 0.72 | F10 (0.71) | F10 | |
| SCHEMBL10280029 | 0.72 | CCR1 (0.39) | ALDH1A1HTTL3MBTL1EPHX2 | |
| SCHEMBL11959792 | 0.71 | DRD2 (0.34) | ALDH1A1L3MBTL1EPHX2MAPK8 | |
| SCHEMBL14306887 | 0.70 | F10 (0.38) | F10 | |
| SCHEMBL1504116 | 0.69 | F10 (0.61) | F10 | |
| SCHEMBL12507711 | 0.68 | MAOA (0.33) | STSL3MBTL1EPHX2F10 | |
| SCHEMBL12056023 | 0.68 | F10 (0.67) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | STS 2128/4885ALDH1A1 793/4885NPC1 4535/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | STS 376/4885ALDH1A1 3734/4885NPC1 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.